Our guest this week is Marcy A. Bliss. It’s pretty easy to take compounded drugs for granted... until things change. And change is in the air starting April 1, 2023, when the Food and Drug Administration’s Guidance for Industry #256 takes effect. GFI 256 will determine what medications veterinary teams are able to keep in their office stock for dispensing to individual patients – such as the bulk order of gabapentin marshmallow-flavored suspension many of us keep on the shelf to send home with those cats and small dogs who just aren’t up for a relaxed experience that day.
Marcy A Bliss, CEO of Wedgewood Pharmacy, joins us to talk about how GFI 256 will change how we use compounded meds, the long list of drugs Wedgewood and others have submitted for review by the FDA in the hopes of getting them approved for office stock, and how veterinarians can influence the FDA to move more drugs onto the “OK” list.
If you’re worried about losing immediate access to the drugs you need, take a few minutes to let the FDA know what drugs are important to you. This page has links to the approved list and the drugs still under review, and makes it easy to submit comments on GFI 256: https://info.wedgewoodpharmacy.com/gfi-comments
Find all of AAHA’s most up-to-date Guidelines, including resources for your clients and team, at aaha.org/guidelines.
Wish you could watch these conversations? Catch Central Line on YouTube.
Got something to say? We’re always up for constructive comments and conversation. Send us feedback or questions anytime at podcast@aaha.org.
This episode was produced by Clear Contender, LLC.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.